Revenue vs Net income
Reported dollars from 10-Q / 10-K filings. Q4 bars are derived (annual less nine months) where the 10-K does not tag Q4 separately.
Margin trend
Gross, operating and net margin. Margins are derived from reported dollars.
Revenue YoY growth
Year-over-year change vs the same quarter (or fiscal year) a year earlier. Shown where the prior-year period is in the 8-quarter snapshot (latest four quarters).
Income statement
From 10-Q / 10-K XBRL. Values in reported dollars; EPS in $/share; share counts in shares.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.5B | $15.1B | $13.3B | $15.4B | $15.8B | $16.6B | $15.0B | $17.0B |
| YoY | — | — | — | — | +9.1% | +10.0% | +12.4% | +10.2% |
| Cost of goods sold | $4.2B | $4.4B | $4.0B | $4.3B | $5.3B | $4.6B | $4.2B | $4.3B |
| YoY | — | — | — | — | +25.9% | +3.5% | +5.4% | -1.3% |
| Gross profit | — | $10.7B | — | — | — | $12.1B | — | — |
| YoY | — | — | — | — | — | +12.7% | — | — |
| Research & development | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Selling, general & administrative | $4.2B | $3.9B | $3.3B | $3.3B | $3.6B | $3.9B | $3.6B | $3.6B |
| YoY | — | — | — | — | -15.1% | +1.0% | +8.7% | +11.7% |
| Operating income | $3.8B | $-1.5B | $3.7B | $4.9B | $1.9B | $4.5B | $4.0B | $6.4B |
| YoY | — | — | — | — | -50.3% | +405.0% | +6.9% | +31.4% |
| Pretax income | $2.1B | $-2.3B | $1.7B | $1.6B | $714.0M | $2.7B | $1.0B | $4.3B |
| YoY | — | — | — | — | -65.7% | +217.6% | -37.4% | +175.3% |
| Income tax | $520.0M | $-2.2B | $372.0M | $613.0M | $526.0M | $853.0M | $342.0M | $662.0M |
| YoY | — | — | — | — | +1.2% | +138.0% | -8.1% | +8.0% |
| Net income | $1.6B | $-22.0M | $1.3B | $938.0M | $186.0M | $1.8B | $695.0M | $3.6B |
| YoY | — | — | — | — | -88.1% | +8354.5% | -46.0% | +285.2% |
| EPS — basic | $0.88 | $-0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 | $2.04 |
| YoY | — | — | — | — | -88.6% | +5200.0% | -45.8% | +292.3% |
| EPS — diluted | $0.88 | $-0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 | $2.03 |
| YoY | — | — | — | — | -88.6% | +5200.0% | -45.8% | +290.4% |
| Weighted shares — basic | 1.77B | — | 1.77B | 1.77B | 1.77B | — | 1.77B | 1.77B |
| Weighted shares — diluted | 1.77B | — | 1.77B | 1.77B | 1.77B | — | 1.77B | 1.77B |
Balance sheet
Point-in-time values at each quarter (or fiscal year) end.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.3B | $5.5B | $5.2B | $6.5B | $5.6B | $5.2B | $9.4B | $6.6B |
| YoY | — | — | — | — | -22.4% | -5.3% | +81.5% | +1.6% |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Accounts receivable | $11.5B | $10.9B | $12.5B | $12.6B | $12.8B | $12.6B | $12.5B | $13.8B |
| YoY | — | — | — | — | +11.3% | +15.3% | +0.0% | +9.4% |
| Inventory | $4.5B | $4.2B | $4.5B | $5.0B | $4.9B | $5.0B | $5.0B | $5.1B |
| YoY | — | — | — | — | +11.0% | +18.4% | +11.6% | +3.4% |
| Total current assets | $27.8B | $25.6B | $27.7B | $29.3B | $28.5B | $29.1B | $33.5B | $33.7B |
| YoY | — | — | — | — | +2.7% | +13.6% | +21.2% | +15.1% |
| Total assets | $143.4B | $135.2B | $136.2B | $137.2B | $133.9B | $134.0B | $136.5B | $135.1B |
| YoY | — | — | — | — | -6.6% | -0.9% | +0.2% | -1.5% |
| Total current liabilities | $43.1B | $38.7B | $36.4B | $39.8B | $39.4B | $43.3B | $42.1B | $41.6B |
| YoY | — | — | — | — | -8.5% | +11.7% | +15.6% | +4.7% |
| Total liabilities | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Total equity | $6.0B | $3.3B | $1.4B | $-183.0M | $-2.6B | $-3.3B | $-6.7B | $-5.9B |
| YoY | — | — | — | — | -143.8% | -198.3% | -568.7% | -3143.2% |
| Shares outstanding | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
Cash flow
Quarterly values derived from year-to-date filings (Q4 from the 10-K). Free cash flow = operating cash flow − capital expenditures.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.4B | $7.0B | $1.6B | $5.2B | $7.0B | $5.2B | $3.8B | $3.4B |
| YoY | — | — | — | — | +29.0% | -26.0% | +134.2% | -33.3% |
| Capital expenditures | $249.0M | $291.0M | $235.0M | $269.0M | $381.0M | $329.0M | $265.0M | $322.0M |
| YoY | — | — | — | — | +53.0% | +13.1% | +12.8% | +19.7% |
| Free cash flow | $5.2B | $6.8B | $1.4B | $4.9B | $6.6B | $4.9B | $3.6B | $3.1B |
| YoY | — | — | — | — | +27.8% | -27.6% | +154.6% | -36.2% |
| Dividends paid | $2.8B | $2.8B | $2.9B | $2.9B | $2.9B | $2.9B | $3.1B | $3.1B |
| YoY | — | — | — | — | +5.8% | +5.8% | +5.5% | +5.5% |
| Share repurchases | $17.0M | $358.0M | $961.0M | $12.0M | $4.0M | $3.0M | $1.5B | $9.0M |
| YoY | — | — | — | — | -76.5% | -99.2% | +54.9% | -25.0% |
Margins & ratios
Derived from the reported dollars above — no separate source.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 70.9% | — | — | — | 72.6% | — | — |
| Operating margin | 26.5% | -9.9% | 28.0% | 31.7% | 12.1% | 27.3% | 26.6% | 37.9% |
| Net margin | 10.8% | -0.1% | 9.6% | 6.1% | 1.2% | 10.9% | 4.6% | 21.3% |
| Free cash flow margin | 35.9% | 44.7% | 10.5% | 31.7% | 42.1% | 29.4% | 23.8% | 18.3% |
| Effective tax rate | 25.0% | 99.0% | 22.4% | 39.4% | 73.7% | 32.0% | 32.9% | 15.5% |
| Current ratio | 0.65x | 0.66x | 0.76x | 0.74x | 0.72x | 0.67x | 0.80x | 0.81x |
| Total liabilities / equity | — | — | — | — | — | — | — | — |
Peer comparison — latest full year
Same sector (Health Care), sorted by revenue. All figures from the same EDGAR XBRL snapshot.
| Ticker | Revenue | Revenue YoY | Gross margin | Operating margin | Net margin | FCF margin |
|---|---|---|---|---|---|---|
| ABBV FY25 · this stock | $61.2B | +8.6% | — | 24.6% | 6.9% | 29.1% |
| UNH FY25 | $447.6B | +11.8% | — | 4.2% | 2.7% | 3.6% |
| CVS FY25 | $402.1B | +7.8% | — | 1.2% | 0.4% | 1.9% |
| CI FY25 | $274.9B | +11.2% | — | 3.3% | — | — |
| ELV FY25 | $199.1B | +12.5% | — | 3.6% | 2.8% | 1.6% |
| JNJ FY25 | $94.2B | +6.0% | 67.9% | — | 28.5% | 20.9% |
| LLY FY25 | $65.2B | +44.7% | — | — | 31.7% | — |
| MRK FY25 | $65.0B | +1.3% | — | — | 28.1% | 19.0% |
| BMY FY25 | $48.2B | -0.2% | — | — | 14.6% | 26.7% |
| TMO FY25 | $44.6B | +3.9% | — | 17.4% | 15.0% | 14.1% |
| ABT FY25 | $44.3B | +5.7% | — | 18.2% | 14.7% | 16.7% |
Source: SEC EDGAR XBRL company facts (10-Q / 10-K), snapshot generated 2026-11-03 for 218 tickers. Q4 values are derived as the 10-K annual less the first nine months, since Q4 is not separately tagged in company facts; cash-flow quarterly values are derived from year-to-date filings the same way. Free cash flow = operating cash flow − capital expenditures. Blank cells mean the filing does not report that line item under a standard US-GAAP tag — nothing is estimated or filled in. Descriptive research, not investment advice. How EarnIQ builds fundamentals.